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Introduction
The current standard treatment for Parkinson's disease (PD) is based on restoration of striatal dopamine (DA) neurotransmission by peripheral administration of the DA precursor L-3,4-dihydroxyphenylalanine (L-DOPA) 1, 2 .
Although L-DOPA is very effective in the early phase of the disease, the majority of PD patients start experiencing adverse effects as the disease progresses. The most prominent are L-DOPA-induced involuntary movements (dyskinesias) that are thought to, at least partly, develop due to the intermittent administration of the drug 3 . Clinical observations suggest that these dyskinesias can be alleviated by constant administration of L-DOPA via either the intravenous or the duodenal route 4, 5 .
Continuous administration of DOPA can also be achieved by viral vectormediated delivery of the genes encoding the enzymes necessary for its production -namely tyrosine hydroxylase (TH) and GTP cyclohydrolase 1 (GCH1). GCH1 is a key enzyme in the synthesis of the cofactor 5,6,7,8-tetrahydro-L-biopterin (BH4). Together, TH and GCH1 are the rate-limiting enzymes in the production of DOPA from the dietary amino acid tyrosine 6 . DOPA is then converted into DA by the aromatic L-amino acid decarboxylase (AADC). By intrastriatal delivery of TH and GCH1 a local and continuous production of DOPA can be achieved, and further decarboxylation presumably occurs in spared serotonergic or dopaminergic neurons 7 . This therapeutic strategy has the potential to alleviate motor complications in PD without induction of dyskinesias or other adverse events induced through off-target DA receptor stimulation.
While other vector types have allowed multi-cistronic expression cassettes containing DA synthesizing enzymes, until now, all studies on the continuous DOPA delivery approach have utilized two separate adeno-associated viral (AAV) vector constructs [8] [9] [10] [11] [12] . In this study we have designed and validated a single AAV vector including both TH and GCH1 (Fig 1) . There are several advantages with a single-vector design. Transduction will assure that both transgenes are coexpressed in the same cells. This is favorable from a clinical translational perspective as it ensures that all transduced cells that drive the transcription of the vector also can synthesize DOPA. Furthermore, by avoiding a mix of two vector constructs, the reproducibility between production batches should also be simplified. We have previously shown that when the two transgenes are delivered from a dual vector injection, at a GCH1:TH ratio of 1:5, optimal DOPA production is achieved 13 . To achieve a favorable stoichiometric relationship in the new single-vector design, we used a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE), down-stream the TH gene. The WPRE sequence functions on the mRNA level (i.e., solely on the expression cassette for the TH gene) through enhancement of mRNA trafficking to the ribosome and increased translation.
In this study, we validated the single AAV vector construct expressing both TH and GCH1 in the complete 6-OHDA lesioned rat PD model with behavioral and biochemical readouts. Therapeutic efficacy was evaluated with several behavioral tests to study functional recovery in simple and complex motor performance and learning tasks. Enzyme function and DA synthesis was studied with online microdialysis, post-mortem biochemistry and histology of transgene expression.
Results

Long-term assessment of functional motor recovery
The therapeutic efficacy of the TH-GCH1 single-vector construct was assessed with a series of behavioral tests. Amphetamine-and apomorphine-induced rotation tests and the cylinder test were performed pre-AAV treatment to validate the 6-OHDA lesion and to balance the experimental groups -the AAV-TH-GCH1 vector treatment group (TH-GCH1) and a lesion control group (Les-Sham). After AAV treatment, the asymmetrical forepaw-use in the cylinder test was restored after 5 weeks in the TH-GCH1 group, and maintained at the 12-and 14-week time points ( Fig. 3a) . Further, the animals were re-assessed with amphetamine-and apomorphine-induction at 10 and 14 weeks, where the TH-GCH1 treatment resulted in a 50 % decrease in rotational bias in both tests ( Fig.   3d ,e). At baseline (post-lesion), the majority of animals displayed a slight ipsiversive spontaneous rotational bias. However, at the beginning of the forth week, animals in the TH-GCH1 group instead started showing indications of contraversive rotational bias. Therefore, all animals' drug-naïve rotational behavior was quantified at week 5, 10 and 14 (Fig 3f) . At week 5, the animals in the TH-GCH1 group rotated close to 60 turns toward the side of injection during the evaluation time, compared to the Les-Sham group that rotated slightly toward the side contralateral to the lesion. At 10 weeks this difference was decreased and at the last assessment there was no significant difference between the groups. Three behavioral tests, in which the animals were not pre-trained, were used to increase the support for the functional efficacy of the TH-GCH1 vector.
Four weeks after AAV treatment, the animals were trained in the stepping test to assess forelimb akinesia by quantifying the ability to do adjusting side steps.
Animals in the Les-Sham group displayed severe impairment in the forepaw contralateral to the lesion (Fig. 3b ). Their performance did not improve over the 14 weeks of assessment. In the TH-GCH1 group, however, the animals showed equal performance on the left paw (contralateral to the lesion) as the right paw.
This recovery was maintained throughout the experiment.
The corridor test was used to study the sensorimotor aspect of the lesion, which was performed as a single assessment at 25 weeks post-AAV treatment. In this test, the read-out variable is the animals' lateralized response selection by nose-pokes in small equally spaced containers filled with sugar pellets along a corridor. Animals in the Les-Sham group showed a strong bias toward retrieving pellets only on the right side (ipsilateral to the lesion) (Fig 3c left) , with only single retrievals on the animals left side (1.3±1.0 % of total retrievals). Again the animals in the TH-GCH1 group displayed a completely symmetrical response (left retrievals 49.6±4.6 % of total) ( Fig. 3c right) .
At 21-24 weeks post-injection of the TH-GCH1 vector, the animals were trained and tested in the staircase version of the paw-reaching test, utilizing a wide platform (35 mm) for maximal stringency of the test. In the test setup on day 1 through 15, both sides of the staircase box were baited with 40 sugar pellets. Day 16-18, only the left staircase was filled, presenting the animals with a forced choice (FC-L) and day 19-21 the opposite staircase was utilized (FC-R).
The animals continuously improved in the number of taken and eaten pellets over day 1-6 (Phase I, learning phase) using both the ipsilateral and contralateral paw ( Fig. 4a,b and d,e ). The rate of learning in both groups was evaluated by regression coefficient comparison over phase I. This confirmed that the two groups improved at the same rate in number of eaten pellets on the ipsilateral paw ( Fig. 4b ), whereas the animals in the TH-GCH1 group improved at a significantly higher rate on the contralateral paw ( Fig. 4e) This was validated by three-way ANOVA that confirmed no significant time effect over days [11] [12] [13] [14] [15] . During the stable phase, the animals in the TH-GCH1 group managed to pickup significantly more pellets on the side contralateral to the lesion, compared to the animals in the Les-Sham group (Fig. 4g ). This was coupled with a significantly greater success in the number of pellets eaten on that side ( Fig. 4h ), resulting in a decreased error rate ( Fig. 4f , i), possibly at the expense of a slightly increased error rate with the intact paw ( Fig. 4c , i).
Efficient BH4 and DOPA synthesis from the single TH-GCH1 AAV vector
For quantitative analysis of the TH-GCH1 gene expression and enzyme function, a subgroup of the animals (n=6 per group) was sacrificed 28 weeks post-AAV treatment for biochemical analysis. Three regions of the forebrain were analyzed in each hemisphere -the dorsal striatum, ventral striatum and the frontal cortex.
Together, these fractions constituted the whole forebrain and thus the total forebrain concentration could be calculated ( Fig. 5 ). As reported previously [13] [14] [15] , the complete 6-OHDA lesion induced an almost 90 % decrease in dorsal striatal BH4 levels (0.16±0.02 pmol/mg compared to 1.4±0.009 pmol/mg) ( Fig. 5a ). The same pattern was observed in the ventral striatum and frontal cortex, although to a lesser extent. The striatal TH-GCH1 injection caused a significant increase in BH4 levels both in the ipsilateral and the contralateral hemisphere. More than eight-fold levels compared to intact levels were observed in the ipsilateral dorsal striatum (11.4±1.5 pmol/mg) and supra-physiological levels were also detected in the ventral striatum and the frontal cortex ( Fig. 5a ). The striatal TH-GCH1 over-expression also led to increased DOPA synthesis. The animals were sacrificed without pre-treatment of a centrally acting AADC enzyme inhibitor such as NSD-1015. Therefore, the DOPA levels observed reflect either a saturation of the AADC enzyme activity or accumulation in sites that do not contain AADC enzyme activity. Whereas the DOPA levels in the intact and lesioned rat brain remained close to the detection limit, the levels in the dorsal striatum ipsilateral to the injection of animals that received the TH-GCH1 vector approached 15 pmol/mg (14.8±1.9 pmol/mg) ( Fig. 5b) . Interestingly, whereas the transduction resulted in increased BH4 levels in the intact hemisphere, there was no detectable increase in DOPA levels in these regions except for the ventral striatum. This further supports our interpretation that accumulation of DOPA is a result of saturation of the AADC enzyme in the denervated forebrain regions and that in the projection region, the contralateral hemisphere, the AADC enzyme is not saturated.
In the rat striatum after a complete 6-OHDA lesion there is no neuronal population that retains the ability to efficiently recover DA from the extracellular space and therefore prevent degradation. While the TH-GCH1 gene delivery reconstituted only 9 % of intact striatal DA levels (5.0±1.2 pmol/mg compared to 56.3±3.6 pmol/mg) ( Fig. 5d ), the DOPAC and HVA levels were reconstituted to 50 % and 200 % respectively ( Fig. 5e ,f). In this study, we also evaluated the effect of the total AADC enzyme activity in the three regions, as the activity of this endogenous enzyme is a key component of the DOPA delivery strategy. In the dorsal striatum, the lesion induced around 85 % decrease in AADC enzyme activity ( Fig. 5c ). In the TH-GCH1 group, decarboxylation activity was decreased around 50 % in ventral striatum whereas it was unaltered in frontal cortex.
Striatal monoamine levels after AAV-mediated TH-GCH1 treatment
Forty-weeks after AAV-treatment, assessment of striatal monoamines was performed with online microdialysis in a subset of animals (TH-GCH1 n=4, Les-Sham n=3, and intact controls n=3. These animals were not followed with behavioral tests). Samples were collected in 15 min time bins in anaesthetized animals and sampling started after 60 min equilibration following the intrastriatal probe placement. Sampling consisted of three baselines samples, a 15 min KCl challenge then followed by four washout samples ( Fig. 6a,b ). Baseline levels of DA in the intact rat striatum were 3.3±0.8 nM, which was significantly decreased by the 6-OHDA lesion. The TH-GCH1 treated animals had higher baseline levels of DA than intact controls (10.5±3.8 nM), however, had much lower release when challenged with KCl (16.0±7.5 nM compared with 176.1±21.5 nM). Animals in the Les-Sham group showed slightly lower release of serotonin (5-HT) when challenged with KCl then intact controls ( Fig. 6b ).
Interestingly, animals in the TH-GCH1 group released substantially lower amounts of 5-HT in response to KCl compared to the Les-Sham group.
Extracellular levels of DOPA and DOPAC followed the same pattern as the total levels quantified post-mortem with high extracellular DOPA levels and partially reconstituted DOPAC ( Fig. 6c,d ). Extracellular HVA levels were however not reconstituted to the same extent ( Fig. 6e ).
Widespread transgene expression in the rodent striatum
Immunohistochemistry was used to qualitatively assess transgene expression.
The injection of 6-OHDA into the medial forebrain bundle in the right hemisphere resulted in a complete loss of the neurons located in the ipsilateral substantia nigra pars compacta and the nuclei they innervate -the striatum and substantia nigra pars reticulata ( Fig. 7a,d ). The 6-OHDA injection also depleted part of the ventral tegmental area that projects to the nucleus accumbens and olfactory tubercle. The contralateral side remained visually unaffected. The twosite injection of the TH-GCH1 vector induced a strong ectopic TH expression in the dorsal, central and caudal striatum ( Fig. 7b ), but also in the cortex and globus pallidus. The GCH1 staining was overlapping with TH but with less intensity (Fig.   7c ). The transduction of striatal projection neurons resulted in an anterograde transport of both TH and GCH1 to the substantia nigra pars reticulata ( Fig. 7e for TH and GCH1 not shown). A clear reduction in NeuN positive cells could be observed in the ipsilateral globus pallidus in vector-treated animals compared with the contralateral side ( Fig. 7f,g) , which was coupled with increased microglial activation, assessed with Iba1 staining (data not shown).
Discussion
The use of a single-vector for co-expression of the TH and GCH1 genes for continuous DOPA delivery has been hampered by the limited packaging capacity of AAV vectors. The yield of the recombinant vector is optimal around the size of the wild-type AAV genome (4.7 kb). If the recombinant genome significantly exceeds this size, the production titers and in vivo efficacy become compromised.
The vector construct tested here uses a somewhat uncommon approach (Fig 1) .
We decided to create two independent expression cassettes where each transgene is expressed from its own promoter. This approach is different from the multicistronic constructs utilized in other studies and gives an important benefit of increased expression predictability 16 . In addition, this is the first clinical candidate vector for enzyme replacement in PD not to utilize a modified form of the cytomegalovirus promoter [17] [18] [19] [20] , but instead an unmodified promoter of human origin. The small synapsin-1 (Syn-1) promoter we used here is preferentially expressed in neurons 21 . Furthermore, adding the WPRE enhancer element in the TH expression cassette, we could amplify the expression of this gene over the GCH1 gene. Presence of the WPRE sequence has been reported to enhance expression in the order of 5-10 fold 22 , bringing it very close to the ratio we have previously determined to be optimal for this approach 13 . As we have found AAV5 to be our serotype preference for this application, both in rats and non-human primates 12,23 , we produced this vector also as that serotype.
We have previously shown that full motor recovery with the continuous DOPA delivery approach could take up to 12 weeks post-AAV treatment 12 . We attributed this to modulation of the down-stream neuronal populations might be required for the symptomatic relief. In this study, we show that this modulation is not required for full recovery in a number of behavioral tests. We did, however, observe emergence of an contraversive rotation bias at 4 weeks post-AAV in the TH-GCH1 group, suggesting a transient over-activation. This is around the time when the expression of the vector reaches maximal level 24 . This effect declined over time suggesting that the post-synaptic modulation and normalization of the basal ganglia circuitry is a slow process, but one that is necessary for normal function to be recognized. Taken together with previous data, this suggests that the post-synaptic plasticity can work to adjust to both a sub-normal and supra-normal synaptic DA concentration, as long as it remains stable 12 . However, the data from this study alone cannot exclude the alternative explanation that there is a slight down-regulation of the transgene expression over time.
The magnitude of normalization in the drug-induced rotation was less than that observed in spontaneous motor behavioral tests. The reduction to about 50 % of baseline apomorphine-induced rotation, in the MFB 6-OHDA lesion model, appear to be somewhat of a floor effect with the AAV-mediated DOPA delivery, as we and others have observed this magnitude with vastly different efficacy of the vector 8, 25 and unpublished observations. However, this appears to be a poor predictor of both protection against L-DOPA induced dyskinesias and recovery in spontaneous motor behavioral tests 12 . The mechanism behind this deserve further investigation.
The study design also included the staircase test to study the effects of continuous DOPA delivery on motor learning. This showed that TH-GCH1 treated animals were quicker to learn how to pickup and eat sugar pellets using the paw affected from the lesion as compared with the Les-Sham group. After the initial 10 days of testing the animals in the treatment group managed to pickup ten more pellets (a 50 % increase) using the affected paw and also ate almost twice as many compared to the Les-Sham group. Motor learning and its dependence on DA has been recently shown in an elegant study in Pitx3 deficient "aphakia" mice where motor learning, independent on motor function, was restored through long-term peripheral L-DOPA administration 26 . Our data suggest that a similar effect is achieved through the AAV-mediated DOPA delivery and that this may contribute to the significant therapeutic potential of the treatment.
The robust behavioral recovery indicates a very efficient DOPA synthesis.
To evaluate the resulting DOPA and DA synthesis capacity and turnover, we measured monoamine content both in the extracellular space in vivo and the total tissue content post-mortem. Striatal monoamine measurements with online microdialysis showed reconstituted levels of baseline DA in the extracellular space. In a previous study by Mandel et al., microdialysis was conducted under similar circumstances but with a two-vector mix of AAV2 vectors with significantly lower transduction and expression efficacy. In this study, extracellular baseline DA levels were below detection limit 11 . Here we show that the DA levels not only could be restored but that even supra-physiological levels could be achieved. This suggests that even though treatment with TH and GCH1 only reconstitutes 9 % of striatal DA levels in tissue homogenates, compared with intact controls, extracellular levels are restored. However, the ability to release through KCl infusion is still limited confirming that storage machinery is not restored with this treatment. This may also explain the less than complete reversal of amphetamine-induced rotation in these animals. However, the reduced 5-HT release suggest that at least a fraction of the de novo synthesized DA is co-stored in the releasable vesicle pool in serotonergic neurons. The One principal requirement a the successful outcome of the continuous DOPA delivery as a clinical therapy is the availability of sufficient decarboxylase activity at the site of transduction 28 . Indeed we find that close to 90 % of the AADC activity in the dorsal striatum appear to reside in DA terminals and is efficiently depleted with the 6-OHDA lesion. We have previously shown that a considerable amount of the residual AADC activity resides in 5-HT terminals in the striatum and that these are indeed important for the symptomatic relief of the therapy 12 . This raises the important consideration of how the availability of AADC is in the human, Parkinsonian brain. While previous studies have shown that the threshold for symptomatic relief of L-DOPA does not increase significantly with disease progression 29 , supporting the concept of a continuous DOPA delivery strategy, other studies have tried to assess the AADC function in the diseased brain. In these studies, the AADC levels appear to be significantly reduced although technical challenges have rendered them highly variable 30, 31 .
More robust findings have been made in MPTP lesioned maqacues where the reduction in AADC activity is suggested to limit the L-DOPA pharmacotherapy 32 .
What implications this may have on the clinical potential for this therapy requires further investigations.
The finding of neuronal loss in the globus pallidus raise questions regarding potential toxicity due to high expression of the transgenes and their products. It has been shown in vitro that high levels of DA and DOPA can cause oxidative stress through formation of reactive oxygen species 33 . Similarly, Chen and colleagues have shown that ectopic accumulation of DA in striatal projection neurons can cause rapid degeneration in a transgenic mouse model 34 
Materials & Methods
Subjects
Forty-four female Sprague-Dawley rats weighing 225-250 g were purchased from Charles River (Germany) and were housed 2-3 per cage with free access to food (except during the staircase and corridor tests, see below) and water under a 12 h light/12 h dark cycle. All experimental procedures performed in this study were approved by the Ethical Committee for use of Laboratory Animals in the Lund-Malmö region. 
Surgical procedures
AAV vector design
The viral vectors utilized in this study were pseudotyped AAV2/5 vectors, where the transgene of interest is flanked by inverted terminal repeats of the AAV2 packaged in an AAV5 capsid (for reasons of simplicity the vectors were referred to as AAV elsewhere in the paper). For this experiment, a novel plasmid was generated, expressing both transgenes, TH and GCH1, under the human Synapsin-1 (Syn-1) promoter (Figure 1) . The cDNA for the human GCH1 gene was followed by a late SV40 poly-A sequence that then preceded the second Syn- The full sequence was terminated by an early SV40 poly-A sequence. The AAV vectors were produced with a double-transfection method with the appropriate transfer plasmid and the helper plasmid containing the essential adenoviral packaging genes, as described previously 39 . They were thereafter purified by iodixanol step gradients and Sepharose Q column chromatography 40 . The purified viral vector suspension was titered with TaqMan quantitative PCR 41 , but with primers and probe targeted toward the WPRE sequence. The final titer of the injected AAV vector suspension was 9.7E13 gc/ml.
Behavioral tests
Drug-induced rotation tests were performed by measuring left and right full body turns with automated rotometer bowls (AccuScan Instruments Inc., Columbus, Ohio), after an injection of either D-amphetamine sulfate (2.5 mg/kg, i.p., Apoteksbolaget, Sweden) or apomorphine-HCl (0.05 mg/kg, s.c., Sigma-Aldrich AB, Sweden) and quantified continuously for 90 and 40 min, respectively.
Rotational asymmetry scores are presented as net full body turns/min, either as ipsiversive (clockwise, i.e., toward the lesion) or contraversive (counter clockwise) rotations. The drug-naïve spontaneous rotation test was performed with the same setup with the exception of the drug challenge.
Cylinder test assessing exploratory forelimb use asymmetry was performed as described by 42 with minor modifications from 43 . Each rat was placed in a 20 cm in diameter glass cylinder and exploratory behavior was recorded with a digital video camera. Two perpendicular mirrors were placed behind the glass cylinder, which allowed the complete surface of the cylinder to be clearly visible on the recording. The animal was left in the cylinder until at least 20 forelimb touches on the cylinder wall were observed. Forelimb placement and use on the cylinder wall was scored off-line with frame-by-frame analysis by an observer blinded to the group identity of the animals. The paw used during each of the 20 contacts with the cylinder walls during rearing was scored and presented as left forepaw touches as a percentage of the total number of touches.
Stepping test was initially described by 44 , and the modified side-stepping version 45 was performed in the this study. Forelimb akinesia was assessed by an investigator blinded to the animals group identity by holding the rat with two hands only allowing one forepaw to reach the table surface. The animal was then moved sideways over a defined distance of 90 cm at a constant pace over 4-5 sec.
The investigator scored the numbers of adjusting side steps in both forehand and backhand direction twice, and the average was calculated. The animals were trained for 6 days during the third week post-AAV injection and then scored by taking the average of their performance during day 7-9, when their daily variability had minimized. During the remaining time points at 10-, 12-and 14weeks post-AAV injection, the animals only needed habituation for one or two days and were then scored during three consecutive days.
Staircase test was used to assess the skilled forelimb reaching and grasping abilities by with a modified version of the original test design described by 46 according to 47 Corridor test was performed 25 weeks post-AAV injections, as previously described 48 to study lateralized sensorimotor response selection. Briefly, the rats were placed in the end of a corridor (1500 x 70 x 230 mm) with 10 adjacent pairs of lids, evenly distributed along the floor. Each lid was filled with approx. 5 sugar pellets. Retrieval was defined as each time the rat poked its nose into a unique cup, regardless of if it ate any pellets. Revisits without interleaving other retrievals were not scored. Each rat was tested until 20 retrievals were made or a maximum time of 5 minutes elapsed. The rats were food restricted prior and throughout testing, as described above for the staircase test, and habituated for 10 minutes for 2 days in the corridor, with sugar pellets scattered along the floor.
To reduce exploratory behavior the rats were placed in an empty corridor before scoring. The rats were then scored for 4 days and the results were presented as an average of the last 2 days of the number of contralateral retrievals (left) as a percentage of total retrievals. 
Histological analysis
Biochemical analysis
Six rats from both the TH-GCH1 and Les-Sham groups were killed by decapitation, where after the brain was removed and sliced in the coronal axis into two parts with a brain mold. The striatal tissue from each hemisphere of the anterior part was then rapidly dissected and frozen individually on dry ice and 
Statistical analysis
All statistics were conducted with the SPSS statistical package (SPSS Inc., Chicago, IL). Repeated measures ANOVA for data in figure 3 After the AAV treatment, the animals in the TH-GCH1 group recovered to full paw use symmetry in the cylinder test within 5 weeks, which was maintained up to 14-weeks post-AAV (a). The stepping test was initiated 4 weeks post-AAV treatment without prior training (b). Also in this test, the animals in the TH-GCH1 group recovered to intact performance already at the first assessment point, which was maintained at the remaining time points at 10-, 12-, and 14-weeks post-AAV treatment. Recovery in the drug-induced rotation tests was less pronounced but was still significant at 14-weeks post-AAV treatment (d, e 
